Tempest Therapeutics (FRA:3OS0) Short Interest


FRA:3OS0 Tempest Therapeutics Inc FRA:3OS0
32 GF Score
Price €5.82
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:3OS0 vs HOWL, INTI, GTBP: Short Interest Comparison

For the Biotechnology subindustry, Tempest Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tempest Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's Short Interest falls into.


FRA:3OS0
32GF Score
Tempest Therapeutics Inc FRA:3OS0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Business Description

Other Exchanges TPST:USA
Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for FRA:3OS0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.82
Price